Thermo Fisher Scientific Inc. $TMO Shares Sold by NBT Bank N A NY

Key Points

• NBT Bank N A NY reduced its holdings in Thermo Fisher Scientific Inc. by 5.9%, now owning 9,546 shares valued at approximately $3.87 million.
• Thermo Fisher Scientific reported a quarterly earnings per share of $5.36, surpassing estimates and showing a 2.9% year-over-year revenue increase.
• Insider trading activity showed significant sales, with executives selling over 30,000 shares valued at around $14.18 million recently.

NBT Bank N A NY lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,546 shares of the medical research company's stock after selling 598 shares during the quarter. NBT Bank N A NY's holdings in Thermo Fisher Scientific were worth $3,871,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Lakeshore Capital Group Inc. grew its position in Thermo Fisher Scientific by 42.7% during the second quarter. Lakeshore Capital Group Inc. now owns 1,330 shares of the medical research company's stock valued at $539,000 after buying an additional 398 shares during the period. Somerville Kurt F increased its holdings in Thermo Fisher Scientific by 1.6% in the 2nd quarter. Somerville Kurt F now owns 1,605 shares of the medical research company's stock worth $651,000 after acquiring an additional 25 shares in the last quarter. REAP Financial Group LLC increased its holdings in Thermo Fisher Scientific by 131.1% in the 2nd quarter. REAP Financial Group LLC now owns 104 shares of the medical research company's stock worth $42,000 after acquiring an additional 59 shares in the last quarter. Sax Wealth Advisors LLC increased its holdings in Thermo Fisher Scientific by 152.6% in the 2nd quarter. Sax Wealth Advisors LLC now owns 1,579 shares of the medical research company's stock worth $640,000 after acquiring an additional 954 shares in the last quarter. Finally, WestEnd Advisors LLC increased its holdings in Thermo Fisher Scientific by 28.5% in the 2nd quarter. WestEnd Advisors LLC now owns 85,492 shares of the medical research company's stock worth $34,665,000 after acquiring an additional 18,950 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $539.54 on Wednesday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The stock has a market cap of $203.73 billion, a PE ratio of 31.21, a P/E/G ratio of 2.95 and a beta of 0.77. The firm has a 50-day simple moving average of $484.90 and a two-hundred day simple moving average of $447.60. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the business earned $5.37 earnings per share. The business's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on TMO shares. William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating for the company. Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Raymond James Financial restated an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, UBS Group raised their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $590.60.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.